BoomerangFX is expanding into AI-powered search advertising with a new marketing technology offering designed to help aesthetic, wellness, and private-pay healthcare practices reach prospective patients through AI-powered discovery platforms. The company is integrating advertising on OpenAI’s ChatGPT with search optimization intelligence for Claude and Gemini into its GROW SaaS platform, connecting patient acquisition with automated engagement and clinic management.
The rollout begins in November 2026 across the United States, Canada, and the United Kingdom. The offering will be available through the GROW Platinum upgrade for existing and new customers.
The launch reflects an emerging advertising opportunity as consumers increasingly use conversational AI tools to research products, services, and healthcare options. According to an August 2026 Pew Research Center report cited by BoomerangFX, 34% of U.S. adults use AI chatbots for at least one health or medical reason.
For healthcare marketers, this creates a potential discovery channel beyond traditional search engines and social advertising. However, visibility within AI-generated answers and access to paid placements remain subject to individual platform policies and availability.
ChatGPT Advertising and AI Search Optimization Enter GROW
BoomerangFX is combining two distinct approaches to AI search marketing: paid advertising opportunities on ChatGPT and organic search optimization for Claude and Gemini.
Its Search Optimization Intelligence capability uses website content and proprietary data science to organize information about treatments, clinician credentials, practice locations, and patient education. The objective is to make this information easier for AI platforms to discover, interpret, and reference when users research healthcare services.
The paid advertising component introduces eligible ChatGPT ad campaigns alongside conventional advertising channels, including Google, Meta, and Instagram.
An important distinction is that paid placements are separate from AI-generated answers. BoomerangFX also acknowledges that platform inclusion, rankings, and recommendations are independently determined by the respective AI providers.
AUVIA Connects Patient Discovery With Conversion
The offering’s operational component is AUVIA, BoomerangFX’s AI Clinic Co-Pilot. Built around a specialized multi-LLM architecture, AUVIA supports patient inquiries, multilingual conversations, lead qualification, consultation scheduling, reminders, and follow-up.
Campaign and conversion signals feed into optimization workflows, connecting advertising activity with patient engagement and booking outcomes.
The platform integrates three principal product areas:
- GROW: Marketing automation, lead management, website intelligence, and patient conversion.
- RUN: Practice management and electronic medical records, including scheduling, digital charting, treatment documentation, billing, payments, and inventory.
- ELEVATE: Marketing strategy, campaign development, paid media, and ongoing optimization.
This integration targets a common operational problem for private-pay clinics: advertising campaigns can generate inquiries, but delayed responses and disconnected booking systems can result in lost prospective patients.
BoomerangFX says AUVIA draws on a specialty knowledge framework covering more than 2,000 treatment and clinical-indication entries. The framework supports contextually relevant patient communication, while clinical assessments and treatment decisions remain the responsibility of healthcare practitioners.
Market Landscape: AI Search Creates a New Advertising Channel
The launch reflects the convergence of AI search optimization, conversational advertising, and marketing automation.
Traditional healthcare marketing has relied heavily on Google search, paid social campaigns, websites, and lead-generation systems. Conversational AI introduces another discovery environment in which prospective patients can ask detailed questions before visiting a clinic website.
For advertisers, this creates opportunities to develop content around treatment information, practitioner expertise, and patient concerns. However, organic AI visibility is not equivalent to guaranteed placement, and advertisers cannot assume that optimization will secure recommendations.
BoomerangFX says its experience includes more than 10,000 Google, Meta, and Instagram campaigns over the past decade. Its strategy is to extend that marketing infrastructure into emerging AI discovery channels while retaining conventional advertising distribution.
Strategic Outlook: From AI Discovery to Patient Acquisition
The commercial significance of BoomerangFX’s launch lies in connecting advertising with the systems responsible for converting inquiries into appointments and managing ongoing patient relationships.
For agencies and healthcare advertisers, integrated campaign management and AI-assisted lead engagement could reduce manual processes and improve operational continuity. For clinics, the combination of marketing, scheduling, payments, and electronic records offers a consolidated technology environment.
However, adoption will depend on ChatGPT advertising availability, advertiser eligibility, platform integration, patient-data governance, and the accuracy of automated healthcare communications.
The initial rollout across the U.S., Canada, and UK will provide an important opportunity for BoomerangFX to establish its position in AI-driven healthcare marketing.
Top Insights
- BoomerangFX is introducing eligible ChatGPT advertising and Claude/Gemini search optimization.
- The offering launches through GROW Platinum in the U.S., Canada, and UK beginning November 2026.
- AUVIA connects AI-powered patient engagement with consultation scheduling and follow-up.
- RUN, GROW, and ELEVATE integrate marketing, practice management, and clinical operations.
- The platform targets aesthetic, wellness, and private-pay healthcare practices.
Get in touch with our Adtech experts.
